Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Mikhail Protopopov¹, Fabian Proft¹, Alexandre Sepriano^2,3, Robert B.M. Landewé^4,5, Désirée van der Heijde², Joachim Sieper¹, Martin Rudwaleit^6,7 and Denis Poddubnyy^1,8, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ⁴Zuyderland Medical Center, Heerlen, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, ⁸German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
Abstract Number: 1189 • 2018 ACR/ARHP Annual Meeting
Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
Dam Kim¹, Hyojin Kim², Seongha Cho² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Patient Access Team, Novartis Korea, Seoul, Korea, Republic of (South)
Secukinumab versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean PerspectiveDam Kim1, Hyojin Kim2, SeongHa Cho2, Min-Chan Park11Division of…
Abstract Number: 1830 • 2018 ACR/ARHP Annual Meeting
Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis
Yukiko Maeda¹, Jozsef Karman² and Ellen M. Gravallese³, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Abbvie Bioresearch Center, Worcester, MA, ³Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) is common, with a prevalence of ~1% in the United States. Patients with SpA suffer from pain and disability due to inflammation…
Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Atul A. Deodhar¹, John D. Reveille², Eric K. H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²University of Texas McGovern Medical School, Houston, TX, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
Abstract Number: 1572 • 2017 ACR/ARHP Annual Meeting
MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects
Geng Wang¹, Adrian Cortes², So-Young Bang³, Paul Leo⁴, Matthew Brown⁴, Tae-Hwan Kim⁵ and Huji Xu¹, ¹Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ²Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, ⁵Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Whilst HLA-B27 is the MHC allele associated with AS, there is strong evidence indicating that other HLA-B alleles and MHC genes are involved in…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 661 • 2017 ACR/ARHP Annual Meeting
Normal Human Enthesis Contains a Resident Population of γδT-Cells
Richard Cuthbert¹, Evangelos M. Fragkakis¹, Robert Dunsmuir², Peter Giannoudis³, Elena Jones¹, Darren Newton⁴ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Spinal Surgery, National Health Service, Leeds, United Kingdom, ³Academic Department of Trauma and Orthopaedics, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recent animal studies have suggested that γδT-cells accumulate at enthesis, secrete IL-17 and are responsible for driving the spondyloarthritis (SpA) phenotype resulting from IL-23…
Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
John D. Reveille¹, Atul A. Deodhar², Eric K.H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹University of Texas McGovern Medical School, Houston, TX, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…
Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Karel Pavelka¹, Alan J. Kivitz², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Alan Slade⁷, Yi Wang⁷, Susanne Rohrer⁸ and Brian Porter⁷, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Altoona Center for Clinical Research, Duncansville, PA, ³MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…
Abstract Number: 2804 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study
Yao-Fan Fang, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan
Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide population study.Background/Purpose: Autoimmune inflammatory diseases influence on pregnancy outcomes. But rare studies have focus on the…
Abstract Number: 992 • 2017 ACR/ARHP Annual Meeting
The Effect of Anti-TNF Therapy on Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis over One Year – Real Life Data from the Czech Biologics Registry Attra
Jakub Zavada¹, Lenka Szczukova², Karel Pavelka³ and Jiri Vencovsky³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: The ATTRA registry captures more than 95% of patients with RA, PSA or AS treated with biologics in the Czech Republic (CZ). In CZ,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].